Premium
Allogeneic haematopoietic stem cell transplantation for myelofibrosis: a report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM‐TC)
Author(s) -
Robin Marie,
Tabrizi Reza,
Mohty Mohamad,
Furst Sabine,
Michallet Mauricette,
Bay JacquesOlivier,
Cahn JeanYves,
De Coninck Eric,
Dhedin Nathalie,
Bernard Marc,
Rio Bernard,
Buzyn Agnès,
Huynh Anne,
Bilger Karin,
Bordigoni Pierre,
Contentin Nathalie,
Porcher Raphaël,
Socié Gérard,
Milpied Noel
Publication year - 2011
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.2010.08417.x
Subject(s) - myelofibrosis , medicine , splenectomy , transplantation , stem cell , hematopoietic stem cell transplantation , haematopoiesis , surgery , gastroenterology , oncology , immunology , bone marrow , spleen , biology , genetics
Summary Allogeneic haematopoietic stem‐cell transplantation (HSCT) is the only curative treatment for myelofibrosis. We report an analysis of the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM‐TC) registry including patients with myelofibrosis transplanted between 1997 and 2008. Potential risk factors affecting engraftment, non‐relapse mortality (NRM), overall survival (OS) and progression‐free survival (PFS) were analysed. One hundred and forty‐seven patients, aged 20–68 (median 53) years, diagnosed with primary (53%) or secondary myelofibrosis underwent HSCT; 59% of patients were transplanted from a matched sibling donor. The conditioning regimen was myeloablative in 31% of patients. Ninety percent of the patients engrafted. Factors affecting favourably engraftment were splenectomy before HSCT, human leucocyte antigen (HLA) matched sibling donor, peripheral stem cell use as source of stem cells and absence of pre‐transplant thrombocytopenia. Four‐year OS, PFS and NRM survival were 39% (95%confidence interval [CI]: 31–50), 32% (95%CI: 24–43) and 39% (95%CI 30–48), respectively. Multivariate analysis indicated that HLA‐identical sibling donor, chronic phase disease and splenectomy in men had favourable impact on OS.